dasotraline
Dasotraline is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that was under development by Sunovion for the treatment of attention-deficit hyperactivity disorder (ADHD) and binge eating disorder (BED). Structurally, dasotraline is a stereoisomer of desmethylsertraline (DMS), which is an active metabolite of the marketed selective serotonin reuptake inhibitor (SSRI) antidepressant sertraline (Zoloft). — Wikipedia
Clinical trial activity
13 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Dec 1, 2007 (NCT00584974)
Timeline
Indications
Mechanism of action
- Monoamine transporterINHIBITOR
Monoamine transporter inhibitor
Dopamine and norepinephrine reuptake inhibitor Dasotraline acts as a potent inhibitor of human DA transporters (DAT; dopamine uptake IC50 3¿nM) and NE transporters (NET; norepinephrine uptake IC50 4¿nM), and a weaker inhibitor of human serotonin transporters (SERT; serotonin uptake IC50 15¿nM)
Chemistry & pharmacology
SMILES
N[C@@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21- Mol. weight
- 292.21 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDasotraline ↗
- ChEMBLCHEMBL3301595 ↗
Also known as
- 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine
- dasotraline
- dasotraline
- dasotraline
- dasotraline
- dasotraline
- sep225289
- sep 225289
- sep-225289
- sep-225289
- sep-225289
- sep-225289
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03231800 | Phase 3 | Jul 31, 2017 | Sunovion |
| NCT03107026 | Phase 3 | Mar 31, 2017 | Sunovion |
| NCT02795637 | Phase 1 | May 1, 2016 | Sunovion |
| NCT02734693 | Phase 3 | Apr 1, 2016 | Sunovion |
| NCT02684279 | Phase 3 | Feb 1, 2016 | Sunovion |
| NCT02564588 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2015 | Sunovion |
| NCT02457819 | Phase 3 | Jun 1, 2015 | Sunovion |
| NCT02428088 | Phase 2/Phase 3 (Phase 3) | Apr 1, 2015 | Sunovion |
| NCT02276209 | Phase 3 | Dec 1, 2014 | Sunovion |
| NCT02195167 | Phase 1 | Jul 1, 2014 | Sunovion |
| NCT02160262 | Phase 3 | Jun 1, 2014 | Sunovion |
| NCT01692782 | Phase 2 | Dec 1, 2012 | Sunovion |
| NCT00584974 | Phase 2 | Dec 1, 2007 | Sunovion |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunovion | For profit | 13 | 13 | 3 | 2007 |